Obsessive Compulsive Disorder associated with Autoimmunity in Youth: Clinical Course before and after Rituximab+/- Adjunctive Immunomodulation
- Case review (n=23) from Stanford on their use of rituximab for presumed-neuroimmune and severe OCD in youth
- Some (47.8%) experienced transient increases in psychiatric or joint pain symptoms before signs of improvement. The time frame for signs of improvement was 3-4 months.
- 70% achieved full or partial recovery at 1-5 years.
- Receiving adjunct immunomodulation was associated with a higher likelihood of achieving full or partial recovery compared with those without adjunct immunomodulation